The Effect of miR-520b on Macrophage Polarization and T Cell Immunity by Targeting PTEN in Breast Cancer

Background Breast cancer is the most common cancer in women. miR-520b had binding sites with PTEN through the bioinformatics prediction. But few studies have been conducted on miR-520b and PTEN in breast cancer. We aimed to explore the effect of miR-520b and PTEN on breast cancer and the mechanisms involved. Methods Clinical samples of breast cancer were collected. Bioinformatics analysis was performed to screen the differentially expressed miRNAs. CD4 T cells and CD8 T cells were cocultured with MCF-7 cells in the Transwell system. Moreover, MCF-7 cells and M0 macrophage cocultured cell lines were constructed. qRT-PCR, IF, western blot, flow cytometry, and ELISA were performed to detect related factors expression. Starbase and dual-luciferase reporter assay verified the binding of miR-520b to PTEN. The tumor formation model was established to study miR-520b and PTEN effects in vivo. Results The differentially expressed miR-520b was screened via miRNAs sequencing and cell verification. miR-520b expression was high, PTEN was low in tumor tissues, T cells and NK cells were inhibited, and macrophages were transformed into M2 type, promoting immune escape. In addition, miR-520b bound to PTEN. Then, splenic CD4 T cells and CD8 T cells were successfully sorted. During CD4 T cell differentiation to Th1 and Treg, Th1 was inhibited, and Treg was activated. We found the polarization of macrophages was related to breast cancer. The proportion of CD206 cells increased and CD68 cells decreased in the miR-520b mimics group compared with the mimic NC group. Compared with the inhibitor NC group, the proportion of CD206 cells decreased, and CD68 cells increased in the miR-520b inhibitor group. In vivo experiments showed that miR-520b inhibitor inhibited tumor growth and promoted PTEN expression. The proportion of CD3, CD4, CD8, NK1.1, CD4+IFNγ, and CD68 cells increased, while FOXP3 and CD206 cells decreased in the miR-520b inhibitor group compared with the inhibitor NC group. However, the proportion of CD3, CD4, CD8, NK1.1, CD4+IFNγ, and CD68 cells decreased, while FOXP3 and CD206 cells increased after the addition of siPTEN. Conclusions miR-520b inhibited PTEN and aggravated breast tumors. miR-520b inhibitor enhanced CD4 and CD8 cell populations in the tumor immune microenvironment and inhibited tumor growth.


Introduction
Breast cancer is the most common cancer in women and the second leading cause of cancer-related deaths [1]. rough epidemiological and clinical studies, the incidence of breast cancer is still on the rise [2]. Breast cancer is a heterogeneous disease whose occurrence and development are mostly related to estrogen, and tumor stratification is crucial for better clinical outcomes [3][4][5]. At present, breast cancer treatment mainly consists of surgical resection, chemotherapy, combined therapy of hormone drugs, and molecular targeting to relieve symptoms and prolong the life of patients [6]. While alleviating cancer, these treatments also greatly affect the patients' quality of life and impose a heavy burden on their families. erefore, seeking a new efficient and low-cost treatment has become an urgent problem for us. microRNAs (miRNAs) are 21-25 long nucleotides that have significantly influenced gene expression [7]. Recently, miRNAs have shown potential as novel biomarkers for many cancers, including breast cancer [7,8]. miRNAs are involved in the metastatic cascade of breast cancer [9,10]. A previous study revealed miR-520b is upregulated in cancer tissues of breast cancer patients, and the level of miR-520b is inversely related to the metastatic potential of breast cancer cells [11]. miR-520b could also promote breast cancer stemness through the Hippo/YAP signaling pathway [12]. ese studies suggest that miR-520b may be a potential diagnostic biomarker and therapeutic target for breast cancer. Interestingly, we found that miR-520b had binding sites with PTEN through the bioinformatics prediction. But few studies have been conducted on miR-520b and PTEN in breast cancer. erefore, we wanted to explore the role of miR-520b and PTEN in breast cancer.
Phosphatase and tensin homolog (PTEN) are tumor suppressors with growth and survival regulatory functions that directly antagonize the PI3K/AKT pathway [13]. PTEN gene can affect a series of biological processes of T lymphocytes, especially in growth, development, proliferation, differentiation, activation, and cytokine secretion [14,15]. However, PTEN gene changes often lead to abnormal T cell responses and even autoimmune diseases and T cell malignancies [16,17]. T cell-mediated immunotherapy is a promising approach to cancer therapy, and PTEN deficiency promotes resistance to T cell-mediated immunotherapy [18]. Kishimoto's study showed that the PTEN gene could lead to a prominent decrease in the number of natural killer T cells and further lead to the deterioration of immunosuppression [19]. In addition, PTEN can regulate CD4 T cells, CD8 T cells, and Treg cells [20]. erefore, it needs to understand PTEN regulatory signals in breast cancer further.
In this study, we screened for miR-520b with significant differences in breast cancer by bioinformatics analysis. In addition, miR-520b could aggravate immunosuppression and accelerate breast cancer progression through PTEN. e results of this study confirmed the importance of miR-520b/ PTEN as a potential biomarker for breast cancer treatment.

Clinical Tissue Samples.
Breast tumor and tumor-adjacent tissue were collected from patients diagnosed with triple negative breast cancer by iconography, serology, or histopathology in the Xiangya Hospital, Central South University, from November 2020 to April 2021. Table 1 shows the demographic characteristics of patients with triple negative breast cancer (n � 30). We had obtained the subjects' written informed consent before the study and received approval from the Medical Ethics Committee of Xiangya Hospital (AF/SQ202104792).

Bioinformatics Analysis.
e data were obtained from the GEO database GSE45666. e clinical samples were divided into breast cancer group (n � 101) and normal group (n � 15). All data were normalized. R package limma screened differentially expressed miRNAs. e selection criteria were |logFC| > 1 [21] and P < 0.05 [22], and the volcano map and heatmap were drawn. en, we used Diana to predict miRNA and found that hsa-miR-520b was upregulated in breast cancer and interacted with PTEN. e network map of hsa-miR-520b and PTEN was plotted by Cytoscape. Diana (http://diana.imis.athena-innovation.gr/ DianaTools/index.php?r�microT_CDS/index) has a score for each pair, and the selection score was set as 0.75.

Cell Culture and Treatment.
Human mammary epithelial cell line MCF-10A and human breast cancer cell line MCF-7 were purchased from the American Type Culture Collection (ATCC, Virginia, USA). MCF-10A cells were cultured in DMEM high glucose with 10% fetal bovine serum (FBS) and 1% penicillin/streptomycin. MCF-7 cells were cultured in DMEM high glucose with 20% FBS and 1% penicillin/streptomycin/amphotericin. All cells were cultured in an incubator at 37°C with 5% CO 2 . According to the instructions, miR-520b mimics, miR-520b inhibitor and its corresponding negative control mimic NC, and inhibitor NC were transfected into the cells using Lipofectamine 3000 reagent ( ermo Fishier Scientific, USA) for subsequent experiments 48 h later. e sequences used are shown in Supplementary Table 1. All sequences were synthesized by Sangon Biotech (Shanghai, China).
To measure the effect of gene changes on naive T cell differentiation, 1 × 10 5 breast cancer cells were inoculated into the lower chamber of the coculture chamber and cultured overnight. 1 × 10 5 CD4 T cells and CD8 T cells were inoculated into the upper chamber of the coculture chamber and cultured for 48 h. en, cell stimulation cocktail (plus protein transport inhibitors) (00-4975-03, eBioscience) was inoculated for 6 h, and T cells were collected for subsequent detection. ey were grouped into the control, mimic NC, miR-520b mimics, inhibitor NC, and miR-520b inhibitor groups.
To observe the polarization of tumor-associated macrophage, breast cancer cells transfected with miR-520b mimics and miR-520b inhibitor were cocultured with M0 macrophage and divided into the control, mimic NC, miR-520b mimics, inhibitor NC, and miR-520b inhibitor groups. Firstly, a single-cell suspension of lymphocytes with a concentration of 1 × 10 7 cells/100 μL was prepared in the cell separation buffer. e cells were then placed in a tube. 20 μL MagniSort TM Enrichment Antibody Cocktail was added to the cells. e cells were washed with a cell separation buffer to a volume of 4 mL and centrifuged at 300 g for 5 min. e supernatant was discarded, and the cells were completely resuspended to their original volume with a cell separation buffer. 20 μL MagniSort TM Negative Selection Beads were added to cells. en, we inserted the tube into the magnet until the bottom of the tube was touching the benchtop through the hole in the bottom of the magnet. We picked up the magnet and in a continuous motion poured the supernatant into a new tube. Finally, we removed the tube containing bound cells from the magnet and discarded it. e untouched, negatively selected cells were ready to use in the new tube. When sorting out CD8 T cells, we picked up the magnet and in a continuous motion poured the supernatant into a 15 mL conical tube. en, we removed the tube containing bound cells from the magnet. Finally, we removed the tube containing bound cells from the magnet and discarded it. e untouched, negatively selected cells were ready to use in the 15 mL conical tube. Flow cytometry assay (A00-1-1102, Beckman) was performed to identify CD4 T and CD8 T cell purity.

Quantitative Real-Time PCR (qRT-PCR)
. qRT-PCR detected hsa-miR-520b, PTEN, Arg-1, and TNFα expressions. To put it simply, total RNA was extracted using the TRIzol method, and the cDNA reverse transcription kit (4368814, Invitrogen, USA) was used to reverse transcript RNA into cDNAs. SYBR Green qPCR Mix (Invitrogen) was applied to detect the relative gene expression on the ABI 7900 system. U6 and β-actin were acted as internal reference genes, and the relative gene levels were calculated by 2 −ΔΔCT method. Table 2 shows primer sequences used in this study.

Enzyme-Linked Immunosorbent Assay (ELISA).
IFNc quantitative ELISA kit (CSB-E04577H, V10034261; CUSABIO) was used to detect IFNc according to the instruction. e concentration of IFNc was calculated using the standard curve provided by Dynatech MR7000 (USA), and the results were expressed as pg/ml.

In Vivo Tumorigenesis.
Sixty SPF-grade, 5-week-old female BALB/c mice were randomly divided into model, inhibitor NC, miR-520b inhibitor, miR-520b inhibitor + siNC, and miR-520b inhibitor + siPTEN groups, with 10 mice in each group. Animal studies were approved by the Medical Ethics Committee of Xiangya Hospital (AF/SQ202104792). Lentiviral vectors miR-520b and PTEN were constructed through Sangon Biotech (Shanghai, China) and transfected in mouse breast cancer 4T1 cells. e sequences used are shown in Supplementary Table 1. For tumor formation, 2 × 10 6 4T1 cells were suspended in 200 μL PBS. en, they were injected into the subcutaneous area. Tumor volume and weight were measured in each group at 28 d. Morphological changes of breast cancer tissues were detected by HE staining.
2.11. HE Staining. HE staining was used to detect the morphological changes of breast tumors in mice. e slices were baked at 60°C for 12 h. e slices were dewaxed to water, stained with hematoxylin for 1 min, and washed with distilled water. en, they were returned to blue with PBS, stained with eosin for 5 min, and rinsed with distilled water. All levels of alcohol (95-100%) were dehydrated for 5 min. After removal, it was placed in xylene for 10 min and then sealed with neutral gum and observed under the microscope.
2.13. Statistical Analysis. GraphPad 8.0 was applied for statistical analysis, and experimental data were expressed as mean ± standard deviation (SD), which was repeated at least three times. Differences between the two groups were analyzed using the student's t-test. One-way analysis of variance (ANOVA) was used for comparison between multiple groups. P < 0.05 was statistically significant.

e Screening of miRNA.
We first screened miRNAs in the GEO database GSE45666. In addition, we did the difference analysis between breast cancer and normal groups. All data were normalized. As shown in Figures 1(a) and 1(b), the volcano map and heatmap were drawn. en, we used Diana to predict miRNAs. e selection score was set as 0.75. We found that hsa-miR-520b was upregulated in breast cancer (Figure 1(c)). In addition, the networks of hsa-miR-520b and PTEN were plotted by Cytoscape (Figure 1(d)). erefore, we focused on studying hsa-miR-520b regulatory mechanism in breast cancer.

e Expression of miR-520b Was High and PTEN Was
Low in Tumor Tissues, and the Immune Microenvironment Was Changed. In order to verify selected miR-520b and PTEN expression levels and to detect miR-520b and PTEN expression by qRT-PCR, clinical breast tumor samples and breast cancer cells were taken. Compared with tumor-adjacent tissues, miR-520b was highly expressed in breast tumor tissues, while PTEN was low expressed (Figure 2(a)). Compared with mammary epithelial cell line MCF-10A, miR-520b was highly expressed in breast cancer cell line MCF-7, while PTEN was low expressed (Figure 2(b)). To investigate whether breast cancer progression was related to immunity, the expression of CD45, CD3, CD4, CD8, and NK1.1 in breast tumor tissues was observed. As shown in Figure 2(c), CD45 immune cells were partially positive in breast tumor tissues, naive T cell marker CD3 was inhibited, and CD4, CD8, and NK1.1 were also inhibited. Further staining for CD206 and CD68 was performed to observe the polarization of breast cancer-associated macrophages. e results showed that CD206 was strongly positive, and CD68 was suppressed in breast tumor tissues compared with adjacent tissue (Figure 2(d)).
ese results indicated that miR-520b expression was high and PTEN was low in tumor tissues, and T cells and NK cells were inhibited, and macrophages were transformed into M2 type, promoting immune escape.

miR-520b
Bound to PTEN, and during CD4 T Cell Differentiated to 1 and Treg, 1 Was Inhibited, and Treg Was Activated. To further explore miR-520b and PTEN role in breast cancer, we first used the Starbase to predict the binding site and dual-luciferase reporter assay to prove      Compared with adjacent tissue, CD206 was strongly positive and CD68 was suppressed in breast tumor tissues. All experiments were repeated three times; * P < 0.05; scale bar � 25 μm; the magnification is 400 times. Differences between the two groups were analyzed using the student's t-test. the binding of miR-520b to PTEN (Figures 3(a) and 3(b)). To measure the effect of gene changes on naive T cell differentiation, CD4 T cells were cocultured with MCF-7 cells in the Transwell system. As shown in Figure 3(c), splenic CD4 T cells and CD8 T cells were sorted out, and the positive proportions of CD4 T cells and CD8 T cells were both reached 85.27%, indicating that splenic CD4 T cells and CD8 T cells were successfully sorted. en, CD4 T cells were counted, and IFNc and FOXP3 were stained to indicate differentiation of 1 and Treg. Compared with the mimic NC group, the proportion of CD4+IFNc cells decreased and FOXP3 cells increased in miR-520b mimics group. e proportion of CD4+IFNc cells increased and FOXP3 cells decreased in miR-520b inhibitor group compared with inhibitor NC group (Figures 3(d) and 3(e); Supplementary Figures 1 and 2). IFNc and FOXP3 expressions were detected in cells cocultured with CD4 T cells and breast cancer cells. Compared with mimic NC group, IFNc expression was decreased and FOXP3 expression was increased in miR-520b mimics group. Compared with the inhibitor NC group, IFNc expression was increased and FOXP3 expression was decreased in the miR-520b inhibitor group (Figure 3(f )).
en, CD8 T cells were cocultured with MCF-7 cells in the Transwell system. CD8 T cells were counted and IFNc was stained to characterize the differentiation of 1. Compared with mimic NC group, the proportion of CD8+IFNc cells decreased in miR-520b mimics group. e proportion of CD8+IFNc cells increased in miR-520b inhibitor group compared with inhibitor NC group (Figure 3(g); Supplementary Figure 3). IFNc secretion of CD4 T cells and CD8 T cells was detected by ELISA, and IFNc levels were decreased in miR-520b mimics group compared with mimic NC group. IFNc levels were increased in the miR-520b inhibitor group compared with the inhibitor NC group (Figure 3(h)). ese results indicated that 1 was inhibited, and Treg was activated during differentiation of CD4 T cell 1 and Treg.

Polarization of Macrophage Associated with Breast
Cancer. To observe the polarization of tumor-related macrophages, CD206 and CD68 were stained by flow cytometry to observe the changes in the cells population. e results showed that the proportion of CD206 cells increased and CD68 cells decreased in miR-520b mimics group compared with mimic NC group. Compared with inhibitor NC group, the proportion of CD206 cells decreased and CD68 cells increased in miR-520b inhibitor group (Figures 4(a) and 4(b); Supplementary Figures 4  and 5). Arg-1 and TNFα were characterized by qRT-PCR and WB to verify the polarization trend of macrophages. As shown in Figures 4(c) and 4(d), compared with mimic NC group, Arg-1 expression in miR-520b mimics group was increased and TNFα was decreased. Compared with inhibitor NC group, miR-520b inhibitor group showed decreased Arg-1 expression and increased TNFα expression.

miR-520b Inhibitor Inhibited Tumor Growth and Promoted PTEN Expression.
To investigate miR-520b and PTEN effects on breast cancer in vivo, we conducted tumorigenesis experiments. Figure 5(a) shows the tumor image of mice. Tumor volume and weight were reduced in the miR-520b inhibitor group compared with the inhibitor NC group. e addition of siPTEN was associated with an increase in tumor volume and weight ( Figure 5(b)). Compared with the inhibitor NC group, miR-520b expression was decreased and PTEN expression was increased in the miR-520b inhibitor group. After adding siPTEN, miR-520b expression was increased, and PTEN expression was decreased ( Figure 5(c)). To further explore the relationship between miR-520b/PTEN and PI3K-Akt pathway, PTEN and PI3K/Akt pathway-related proteins expressions were detected by WB. Compared with the inhibitor NC group, PTEN was increased and p-PI3K and p-AKT expressions were decreased in miR-520b inhibitor group. After adding siPTEN, PTEN expression decreased, and p-PI3K and p-AKT expression increased ( Figure 5(d)). HE staining was used to measure the morphological changes of breast cancer tissues. As shown in Figure 5(d), the cytoplasm was stained with eosin to different degrees of red or pink, in sharp contrast to the blue nucleus stained with hematoxylin. e red arrows were used to indicate inflammatory cells. Compared with the inhibitor NC group, the inflammatory infiltration of breast cancer tissue was decreased in the miR-520b inhibitor group, while increased after adding siPTEN. ese revealed that miR-520b inhibitor inhibited tumor growth and promoted PTEN expression, and siPTEN reversed this effect.

miR-520b Inhibitor Enhanced T Cell Activation in the Tumor Environment and Guided the Polarization of Macrophages to M1, ereby Inhibiting Tumor Growth.
To explore miR-520b inhibitor effect on the number of T cells and macrophages, CD3, CD4, CD8, NK1.1, CD4+IFNc, FOXP3, CD206, and CD68 expressions were detected by flow cytometry. e proportion of CD3, CD4, CD8, and NK1.1 cells increased in miR-520b inhibitor group compared to inhibitor NC group. However, the proportion of CD3, CD4, CD8, and NK1.1 cells decreased after the addition of siPTEN (Figure 6(a); Supplementary Figures 6-9). Figure 6(b) reveals the proportion of CD4+IFNc cells increased and FOXP3 cells decreased in the miR-520b inhibitor group compared with the inhibitor NC group. e proportion of CD4+IFNc cells decreased and FOXP3 cells increased after the addition of siPTEN ( Supplementary Figures 10 and 11).
ese results indicated that during CD4 T cells differentiated to 1 and Treg, 1 was inhibited, and Treg was activated. To detect the polarization of tumor-related macrophage, flow cytometry was used to stain CD206 and CD68, and the changes in cell population were observed. e results showed that the proportion of CD206 cells decreased and CD68 cells increased in miR-520b inhibitor group compared with inhibitor NC group. However, the proportion of CD206 cells increased and CD68 cells decreased after the addition of siPTEN (Figure 6(c); Supplementary Figures 12  and 13). ese findings suggested that miR-520b inhibitor

Discussion
Breast cancer seriously affects life quality. However, there is a lack of new effective and low-cost treatments. In our paper, we identified differentially expressed miR-520b in breast cancer based on bioinformatics analysis. In addition, through verification, we found that miR-520b and PTEN could interact with each other. Based on this, we conducted a large number of experiments; the results revealed miR-520b accelerated breast cancer progression by aggravating immunosuppression through PTEN. miRNAs can be used as early indicators of dietary and physical activity responses in women with metastatic breast cancer [25]. Studies have shown miR-520b promotes doxorubicin-induced breast cancer cell apoptosis by regulating the PI3K/AKT signaling pathway [26]. Cui et al. reported that miR-520b could contribute to complementdependent cytotoxicity in breast cancer cells via directly targeting the 3′UTR of CD46 [27]. In Xing et al.'s study, they found that circIFI30 promoted triple negative breast cancer progression through the circIFI30/miR-520b-3p/CD44 axis [28]. ese findings suggested that miR-520b was closely related to breast cancer occurrence and development.
Interestingly, we found that miR-520b had binding sites with PTEN. However, there are few studies on miR-520b and PTEN at present. Our study verified that miR-520b could bind with PTEN. Moreover, miR-520b inhibitor could inhibit tumor growth, promote PTEN expression, and antagonize PI3K/AKT pathway. is is also the innovation of our research. e tumor microenvironment (TME) in breast tumors has recently become an important participant in tumor progression [29]. Among them, tumor-associated macrophages (TAMs) are the main component of TME in breast cancer [30].
e immune system is very active in breast cancer and plays a dual role in tumor progression and immune monitoring [31]. Infiltration of immune cells predicts prognosis and response to standard breast cancer therapy [32]. According to the presence of microenvironmental signals, macrophages are polarized into two different phenotypes, classical activated (M1) or activated (M2) macrophages [33]. However, TAMs are very similar to M2 polarization [34]. Li et al. reported that TAM secreted CCchemokine ligand 2 and induced tamoxifen resistance by activating PI3K/Akt/mTOR in breast cancer, and high expression of CC-chemokine ligand 2 was correlated with infiltration of CD163+ macrophages [35]. Our study showed that CD45 immune cells were partially positive in breast tumor tissues, naive T cell marker CD3 was inhibited, and CD4, CD8, and NK1.1 were also inhibited. In addition, CD206 was strongly positive and CD68 was suppressed in Compared with mimic NC group, IFNc expression was decreased and FOXP3 expression was increased in miR-520b mimics group. Compared with the inhibitor NC group, IFNc expression was increased and FOXP3 expression was decreased in the miR-520b inhibitor group. (g) e proportion of CD8+IFNc cells. Compared with mimic NC group, the proportion of CD8+IFNc cells decreased in miR-520b mimics group. e proportion of CD8+IFNc cells increased in miR-520b inhibitor group compared with inhibitor NC group. (h) ELISA detected IFNc levels. IFNc levels were decreased in miR-520b mimics group compared with mimic NC group. IFNc levels were increased in the miR-520b inhibitor group compared with the inhibitor NC group. All experiments were repeated three times; * P < 0.05 vs the control group, # P < 0.05 vs the mimic NC group, and P < 0.05 vs the inhibitor NC group. Differences between the two groups were analyzed using the student's t-test. One-way analysis of variance (ANOVA) was used for comparison between multiple groups.
breast tumor tissue, indicating that the immune microenvironment in the tumor tissue was changed.
Tumor-infiltrating lymphocytes are associated with neoadjuvant chemotherapy response and prognosis in breast cancer [36]. CD4 T cells are essential for maintaining antiviral immunity [37]. CD8 T cells are a vital branch of adaptive immunity, helping to clear intracellular pathogens and provide long-term protection [38]. However, both CD4 and CD8 T cells increase and participate in immune response, showing an obvious dynamic trend in the e proportion of CD206 cells increased and CD68 cells decreased in miR-520b mimics group compared with mimic NC group. Compared with inhibitor NC group, the proportion of CD206 cells decreased and CD68 cells increased in miR-520b inhibitor group. (c, d) qRT-PCR and WB measured Arg-1 and TNFα levels, respectively. Compared with mimic NC group, Arg-1 expression in miR-520b mimics group was increased and TNFα was decreased. Compared with inhibitor NC group, miR-520b inhibitor group showed decreased Arg-1 expression and increased TNFα expression. All experiments were repeated three times; * P < 0.05 vs the control group, # P < 0.05 vs the mimic NC group, and P < 0.05 vs the inhibitor NC group. Differences between the two groups were analyzed using the student's t-test. One-way analysis of variance (ANOVA) was used for comparison between multiple groups. 14 Journal of Oncology development of breast cancer [39].
1/ 2 balance is associated with antitumor immunity in breast cancer [40]. Treg cells control tissue homeostasis by fighting local inflammation [41]. Saleh et al. thought tumor Syndecan-1 silencing could enhance ex vivo polarization of CD4+ 17 and Treg cells of noninflammatory breast cancer [42]. It has been reported that as tumor cells metastasize to lymph nodes and progression of disease stages, the immune response shifts from an inflammatory state to an inhibited state, with a decrease in proinflammatory and antitumor cytokines, IL17 and IFNc, and an increase in protumor phenotypes, 2 and Treg cells [43]. Our results showed that during CD4 T cell differentiated to 1 and Treg, 1 was inhibited and Treg was activated. miR-520b inhibitor enhanced the activation of T cells in the tumor environment, guided the polarization of macrophages to M1, and changed the immune microenvironment of breast tumors, thereby inhibiting tumor growth. Compared with the inhibitor NC group, PTEN was increased and miR-520b, p-PI3K, and p-AKT expressions were decreased in miR-520b inhibitor group. After adding siPTEN, PTEN expression decreased, and miR-520b, p-PI3K, and p-AKT expression increased. (e) HE staining measured morphological changes of breast cancer tissues. e inflammatory infiltration of breast cancer tissue was decreased in the miR-520b inhibitor group, while increased after adding siPTEN. e cytoplasm was stained with eosin to different degrees of red or pink, in sharp contrast to the blue nucleus stained with hematoxylin. e red arrows were used to indicate inflammatory cells. All experiments were repeated three times; # P < 0.05 vs the inhibitor NC group, and P < 0.05 vs the miR-520b inhibitor + siNC group. Scale bar � 25 μm, the magnification is 400 times; scale bar � 100 μm, the magnification is 100 times. Differences between the two groups were analyzed using the student's t-test. One-way analysis of variance (ANOVA) was used for comparison between multiple groups.
However, there are some limitations to our article. Our research is not deep enough, and we need to study further the effect of miR-520b and PTEN on macrophage polarization and T Cell Immunity in breast cancer in the future. We only used the GSE45666 dataset to discriminate miRNA expression differences between adjacent normal and tumor tissues of breast cancer. Next, we will select multiple data datasets for screening. In addition, the coculture cell ratio used in the experiment was 1 : 1. Although preexperimental screening was carried out, multiple dilution ratios should be , and CD68 cells increased, while FOXP3 and CD206 cells decreased in miR-520b inhibitor group compared with inhibitor NC group. However, the proportion of CD3, CD4, CD8, NK1.1, CD4+IFNc, and CD68 cells decreased, while FOXP3 and CD206 cells increased after the addition of siPTEN. All experiments were repeated three times; # P < 0.05 vs the inhibitor NC group, and P < 0.05 vs the miR-520b inhibitor + siNC group. Differences between the two groups were analyzed using the student's t-test. One-way analysis of variance (ANOVA) was used for comparison between multiple groups.
selected for comparative study. In the future, we would like to further study the effect of miR-520b and PTEN on macrophage polarization and Tcell immune in the ratio of 1 : 5 and 1 : 10.

Conclusions
In brief, our results suggested miR-520b accelerated breast cancer progression by aggravating immunosuppression through PTEN. is paper provided targets for clinical treatment and prognosis judgment of breast cancer and helped to enrich novel treatment strategies for breast cancer.

Data Availability
e data used to support the findings of this study are available from the corresponding author upon request.

Conflicts of Interest
e authors declare that there are no conflicts of interest regarding the publication of this paper.

Supplementary Materials
Supplementary Table 1. e sequence details of mimics and inhibitors used in this study. Supplementary Figure 1. e complete panel of the proportion of CD4+IFNc cells. e groups were divided into the control, mimic NC, miR-520b mimics, inhibitor NC, and miR-520b inhibitor groups. Compared with the mimic NC group, the proportion of CD4+IFNc cells decreased in miR-520b mimics group, while the proportion of CD4+IFNc cells increased in miR-520b inhibitor group compared with inhibitor NC group. Supplementary Figure 2. e complete panel of the proportion of FOXP3 cells. e groups were divided into the control, mimic NC, miR-520b mimics, inhibitor NC, and miR-520b inhibitor groups. Compared with the mimic NC group, the proportion of FOXP3 cells increased in miR-520b mimics group. However, the proportion of FOXP3 cells decreased in miR-520b inhibitor group compared with inhibitor NC group. Supplementary Figure 3. e complete panel of the proportion of CD8+IFNc cells. e groups were divided into the control, mimic NC, miR-520b mimics, inhibitor NC, and miR-520b inhibitor groups. Compared with mimic NC group, the proportion of CD8+IFNc cells decreased in miR-520b mimics group. e proportion of CD8+IFNc cells increased in miR-520b inhibitor group compared with inhibitor NC group. Supplementary Figure 4. e complete panel of the proportion of CD206 cells. e groups were divided into the control, mimic NC, miR-520b mimics, inhibitor NC, and miR-520b inhibitor groups. e proportion of CD206 cells increased in miR-520b mimics group compared with mimic NC group. Compared with inhibitor NC group, the proportion of CD206 cells decreased in miR-520b inhibitor group. Supplementary Figure 5. e complete panel of the proportion of CD68 cells. e groups were divided into the control, mimic NC, miR-520b mimics, inhibitor NC, and miR-520b inhibitor groups. e proportion of CD68 cells decreased in miR-520b mimics group compared with mimic NC group. Compared with inhibitor NC group, the proportion of CD68 cells increased in miR-520b inhibitor group. Supplementary Figure 6. e complete panel of the proportion of CD3 cells. e groups were divided into the model, inhibitor NC, miR-520b inhibitor, miR-520b inhibitor + siNC, and miR-520b inhibitor + siPTEN groups. e proportion of CD3 cells increased in miR-520b inhibitor group compared with inhibitor NC group. However, the proportion of CD3 cells decreased after the addition of siPTEN. Supplementary  Figure 7. e complete panel of the proportion of CD4 cells. e groups were divided into the model, inhibitor NC, miR-520b inhibitor, miR-520b inhibitor + siNC, and miR-520b inhibitor + siPTEN groups. e proportion of CD4 cells increased in miR-520b inhibitor group compared with inhibitor NC group. However, the proportion of CD4 cells decreased after the addition of siPTEN. Supplementary  Figure 8. e complete panel of the proportion of CD8 cells. e groups were divided into the model, inhibitor NC, miR-520b inhibitor, miR-520b inhibitor + siNC, and miR-520b inhibitor + siPTEN groups. e proportion of CD8 cells increased in miR-520b inhibitor group compared with inhibitor NC group, while the proportion of CD8 cells decreased after the addition of siPTEN. Supplementary  Figure 9. e complete panel of the proportion of NK1.1 cells. e groups were divided into the model, inhibitor NC, miR-520b inhibitor, miR-520b inhibitor + siNC, and miR-520b inhibitor + siPTEN groups. e proportion of NK1.1 cells increased in miR-520b inhibitor group compared with inhibitor NC group, while the proportion of NK1.1 cells decreased after the addition of siPTEN. Supplementary  Figure 10.
e complete panel of the proportion of CD4+IFNc cells. e groups were divided into the model, inhibitor NC, miR-520b inhibitor, miR-520b inhibitor + siNC, and miR-520b inhibitor + siPTEN groups. e proportion of CD4+IFNc cells increased in miR-520b inhibitor group compared with inhibitor NC group. However, the proportion of CD4+IFNc cells decreased after the addition of siPTEN. Supplementary Figure 11. e complete panel of the proportion of FOXP3 cells. e groups were divided into the model, inhibitor NC, miR-520b inhibitor, miR-520b inhibitor + siNC, and miR-520b inhibitor + siPTEN groups. e proportion of FOXP3 cells decreased in miR-520b inhibitor group compared with inhibitor NC group, while the proportion of FOXP3 cells increased after the addition of siPTEN. Supplementary  Figure 12. e complete panel of the proportion of CD206 cells. e groups were divided into the model, inhibitor NC, miR-520b inhibitor, miR-520b inhibitor + siNC, and miR-520b inhibitor + siPTEN groups. e proportion of CD206 cells decreased in miR-520b inhibitor group compared with inhibitor NC group. However, the proportion of CD206 cells increased after the addition of siPTEN. Supplementary  Figure 13. e complete panel of the proportion of CD68 cells. e groups were divided into the model, inhibitor NC, miR-520b inhibitor, miR-520b inhibitor + siNC, and miR-520b inhibitor + siPTEN groups. e proportion of CD68 cells increased in miR-520b inhibitor group compared with inhibitor NC group, while the proportion of CD68 cells decreased after the addition of siPTEN. (Supplementary Materials)